What kind of supporting documentation is required for PAR submission?
Supporting documentation may consist of:
Chart notes confirming the patient’s diagnosis
Dosage and history of treatment with requested medication
History of prior medications which have been tried and failed
Additional information which may be requested as needed
What are the turnaround times (TAT) for a PAD PA determination to be made?
From the time a completed request is received (a request is complete upon submission of all pertinent information)
PAD Prospective Standard Request: 24 hours TAT
PAD Urgent (Expedited) Request (must meet the urgent request standards): 4 hours TAT
All requested information submitted on the portal as a response to a request for more information (RFI): 24 hours TAT
What constitutes an Urgent (Expedited) Request?
An expedited PAD PAR is that which is urgent (expedited) because a delay in treatment could:
Jeopardize the life or limb of the member OR
Jeopardize the member’s ability to attain, regain, and/or maintain maximum function
Remicade is listed as requiring a PA – what about biosimilar drugs?
Only the HCPCS and PADs listed on Appendix Y require a PA
What are the next steps after a PAR is denied?
Following a PAR denial, there are three potential options which may be pursued:
Reconsideration Request
The provider may request a reconsideration to Acentra within ten (10) days of the initial denial
Additional information and documentation must be submitted for reconsideration of the PAR
Peer to Peer (P2P) Request
The provider may request a Peer-to-Peer review within five (5) days from the date of the medical necessity adverse determination.
A P2P cannot be performed on a technical or administrative denial.
Formal Appeal
Additional information will be provided in denial letters
Process must be pursued by the member
It is strongly encouraged that a provider exhaust both reconsideration and P2P options prior to a member pursuing a formal appeal.
How often will Appendix Y be updated?
Appendix Y may be updated on an as needed basis and usually in conjunction with determinations made during the review of PA criteria at quarterly Drug Utilization Review Board (DUR) meetings.
Information related to the DUR Board, including meeting agendas can be found on the Drug Utilization Review Board web page.